Latest news and press releases about Advanced Biomed Inc. Common Stock (ADVB): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Advanced Biomed Inc. functions as an investment holding company, primarily dedicated to the research and development of microfluidic biochip technologies. Based in Taiwan, the company leverages these innovations to enhance precision oncology, spanning cancer detection, diagnosis, and treatment. Its diverse product portfolio includes a suite of advanced devices: A+Pre: A fully automated system designed for pre-concentrating diluted blood samples.
Price
| Price | $7.72 |
| Market Cap | $11M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 1.04 |
| EV / EBITDA | -10.96 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -20.71% |
| Return on Invested Capital | -11.04% |
| Return on Assets | -6.36% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: APM · BGLC · CHEK · GELS · MBIO · MRKR · RDGT
Explore sector: Healthcare · Medical - Diagnostics & Research
More sections of ADVB: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks